Biologics: an update and challenge of their pharmacokinetics.
about
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic ProteinsTransfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheepA comparison of biophysical characterization techniques in predicting monoclonal antibody stability.Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Biosimilar monoclonal antibodies: the scientific basis for extrapolation.Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.The Isoxazole Ring and Its N-Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics.Considerations for dosing immunoglobulin in obese patients.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.Evaluation of Gallium as a Tracer of Exogenous Hemoglobin-Haptoglobin Complexes for Targeted Drug Delivery Applications.Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer.Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients.Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation.Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.Ligandomics: a paradigm shift in biological drug discovery.Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe
P2860
Q28066498-525DC190-BE26-41AD-A211-A4B8624BF281Q33912465-D69C979E-D92F-4BFC-9A7E-8C500B43F376Q37287010-6BD536E3-131D-4552-8F45-D1B45462B5C9Q37600387-F055FEE9-71C8-48B5-960F-1F9F295EDD0CQ38289992-6C22E6C9-2D11-43B8-8671-B7ABC8FFEFA2Q38586044-85886985-08C8-4AB9-8587-E2E27BF5A55CQ38790368-29BE292B-F9C7-4BA0-8FD2-B73E54FFFD8EQ38962519-3F99C71D-05AE-4F40-8B02-B44394514020Q39034676-0E89778B-AB03-4C43-A44F-6EE8E0ADC7E6Q39157903-6A1987E7-B892-460A-B917-60A4B229A75AQ39163785-9528187D-7806-407D-9425-D7AD79A81A52Q39277950-40A8D776-DC9A-4E2D-81A7-CBB086B8ECA8Q39731345-261855D9-0C7E-4390-B6ED-BA51AAD10601Q40505663-53A45460-8922-47F9-A9D8-C5C280DD1A32Q41245735-B8DC6F11-49E6-4BCC-9A1E-C561DBD49BD4Q41322794-3A5979AD-AA18-45C6-98D4-943796640543Q41463031-61F64B1D-1940-4518-8FA1-99DC31E990B9Q41758222-D891C6D7-1600-4327-ADD2-DA44C77841A9Q46242399-E9453F17-8558-42B3-BCDF-AD3BFB95E8FFQ50078681-A8CE4B55-46BC-4166-8580-79B19102C445Q59129650-2C767051-01DF-4C8E-B1BF-5027245A0E0D
P2860
Biologics: an update and challenge of their pharmacokinetics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biologics: an update and challenge of their pharmacokinetics.
@en
type
label
Biologics: an update and challenge of their pharmacokinetics.
@en
prefLabel
Biologics: an update and challenge of their pharmacokinetics.
@en
P1476
Biologics: an update and challenge of their pharmacokinetics.
@en
P2093
Shaojun Shi
P304
P356
10.2174/138920021503140412212905
P407
P577
2014-03-01T00:00:00Z